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Neuroimmunophilin Ligands 
Recently a number of groups have disclosed novel compounds derived from the 
peptidylprolyl isomerase (PPIase) inhibition domains of the immunosuppressive drugs FK506 
and rapamycin. These non-immunosuppressive small molecules, with a molecular weigh of 
less than 500, were found to be potent neurotrophic agents in neurite outgrowth assays. 
Certain analogues, such as GPI 1046 (i) have also been shown to be effective in models of 
Parkinson’s and Alzheimer’s diseases. Dosing paradigms have shown these compounds to 
product both neuroprotective and neuroregenerative effects in models of CNS pathogenicity. 
The biological target for the exceptional neurotrophic activity of compounds such as (i) is not 
known, although FKBP-12 is a likely candidate since it is upregulated in models of CNS 
injury. It has been shown, however, there is no clear correlation between rotamase inhibition 
activity and ED50 for neurite outgrowth. 
In an effort to produce Structure Activity Relationships (SAR) in one compound series, 
thereby helping to separate neuroprotective from neuroregenerative properties of these 
compounds, a library of compounds targeting neuroimmunophilin was synthesised (Solid-
phase/solution-phase combinatorial synthesis of neuroimmunophilin ligands, M. Rabinowitz 
et. al., Bioorg. Med. Chem. Lett., 10, (2000), 1007-1010). A library of 880 individual 
compounds was synthesised in solution, in which the central amino acid core present in (i) 
was kept constant, and the other substituents varied. These compounds were tested in a 
FKBP-12 SPA binding assay. Of those compounds tested, all possessed lower affinity for this 
protein compared to FK506 and rapamycin, e.g., (ii) which displayed a pIC50 of <5. The 
success of this library protocol may facilitate future endeavours in the search for SAR in this 
series where the amino acid core is also varied. 
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α5β3 Integrin antagonists 
The inhibition of the α5β3 integrin receptor is regarded as a promising goal in the therapy of 
various pathophysiological processes such as tumour-induced angiogenesis, restenosis, 
osteoporosis and acute renal failure. The amino acid sequence Arg-Gly-Asp (RGD), which 
can be recognised by the α5β3 receptor and by at least ten additional integrins, has been used 
as a lead structure in the development of α5β3 inhibitors. The split synthesis paradigm allows 
large combinatorial libraries to be produced rapidly, and has been used for the synthesis of a 
diacylhydrazine library and its biological on-bead evaluation using a soluble α5β3 integrin 
receptor (Nonpeptidic α5β3 integrin antagonist libraries: on-bead screening and mass 
spectrometric identification without tagging, H. Kessler et. al., Angew. Chem. Int. Ed., 40, 
(2001), 165-169). 
A library of 990 compounds, synthesised from TentaGel Macrobeads, was prepared in 
mixtures of 33. Of those compounds synthesised, active mixtures were identified upon 
incubation of the beads with soluble, biotinylated α5β3 receptor and subsequently with a 
monoclonal antibiotin alkaline phosphatase conjugate. These mixtures were then 
deconvoluted and synthesised as single entities, this time from Rink amide (MBHA) resin. 
One of the most active compound identified was (iii) which displayed an (IC50) affinity for 
the α5β3 receptor of 150 nM, with 48 fold selectivity over α5β5 and > 666 fold selectivity over 
αIIbβ3. This work illustrates the potential for discovering new, low molecular weight integrin 
ligands through application of combinatorial solid-phase synthesis and biological on-bead 
evaluation. 
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Substrates for novel proteases 
A large number of potential targets for therapeutic intervention of both human and microbial 
origin is expected to become available through genomics. One of the major challenges is to 
prioritise these targets. Homology with known genes and information about the location and 
temporal expression of the genes will be used in the prioritisation process. Genes that are 
preferentially expressed in diseased tissue, compared to healthy tissues, are likely to be 
potential targets. Proteolytic enzymes represent one major class of targets since they are 
involved in a wide variety of disorders including infection diseases and other pathologies. 
There is a need for optimal substrates to study enzymology of the selected proteases, for 
validation as relevant medicinal targets and to screen for inhibitors. Sensitive fluorescence 
resonance energy transfer (FRET) experiments are extensively used in biomedical research 
for this purpose. A combinatorial chemistry approach can be used for the rapid identification 
of fluorogenic substrates, allowing for the development of high throughput screening assays 
for the fast and reliable testing of compound libraries against an increasing number of targets. 
The technology consists of a solid-phase enzyme assay system using polymer-bound peptide 
libraries built up by split synthesis, and is based on the principal of FRET (Rapid 
identification of substrates for novel proteases using a combinatorial peptide library, J. Comb. 
Chem., 2, (2000), 461-466). 
A library of theoretical size 260,642 individual peptides, targeting leader peptidases, which 
are integral membrane proteins that catalyse the removal of the signal peptides of proteins 
exported to the periplasm, was synthesised on PEGA1900 solid-phase resin. Incubation of the 
beads with E. coli leader peptidase gave bright fluorescent beads with active peptides. These 
were harvested and the active amino acids within these sequences identified to provide the 
exact site of enzyme cleavage on the peptide chain. Following deconvolution of active 
mixtures, and re-synthesis of these peptides as single compounds, peptide (iv) was isolated 
and found to display the greatest affinity for the enzyme, with a Km of 0.43 x10
-6M. The 
benefits of this technology are that it can be performed on single beads and rapidly access 
motifs within peptides recognised by enzyme substrates. It may also find use in determining 
fluorogenic substrates for novel, poorly characterised proteases. 
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